Share ownership Savara Inc.

SVRA

US8051111016

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 14:51:26 14/07/2026 BST			5-day change	1st Jan Change
5.725 ^USD	-0.26%		-9.18%	-6.47%

06-23	Savara Insider Sold Shares Worth $2,241,432, According to a Recent SEC Filing	MT
06-08	Savara Inc. Announces CFO Changes	CI

Share class: Savara Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	204,927,212	199,649,646 ( 97.42 %)	0	97.42 %

Major shareholders: Savara Inc.

Name	Stocks	%	Valuation
NEA Management Co. LLC 11.94 %	24,471,264	11.94 %	151 M $
Bain Capital Life Sciences LP 8.589 %	17,600,621	8.589 %	108 M $
Venrock Associates 6.705 %	13,740,375	6.705 %	85 M $
Deerfield Management Co. LP (Private Equity) 6.621 %	13,569,000	6.621 %	84 M $
TCG Crossover Management LLC 6.032 %	12,362,205	6.032 %	76 M $
TCG Crossover Management LLC 6.032 %	12,362,205	6.032 %	76 M $
BlackRock Advisors LLC 5.219 %	10,696,051	5.219 %	66 M $
Frazier Life Sciences Management LP 4.744 %	9,720,852	4.744 %	60 M $
POLAR CAPITAL HOLDINGS PLC 4.656 %	9,541,786	4.656 %	59 M $
Vanguard Capital Management LLC 3.798 %	7,783,913	3.798 %	48 M $
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	97.77%
Others	4.7%
Polar Capital Holdings Plc	4.66%
State Street Corp.	3.27%
Individuals	2.67%
Swedbank AB	0.34%
Schweizerische Nationalbank	0.07%
Manulife Financial Corp.	0.03%
Fifth Third Bancorp	0.03%
SEI Investments Co.	0.02%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	97.32%
United Kingdom	8.24%
Individuals	2.67%
Canada	1.7%
Switzerland	1.2%
Hong Kong	0.9%
Israel	0.36%
Sweden	0.34%
Germany	0.34%
Cayman Islands	0.19%
France	0.15%
Ireland	0.08%
China	0.03%
Singapore	0.02%
Norway	0.01%
South Korea	0.01%

Based on 1000 largest holdings

Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Companyâ€™s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Employees

Sector

Biotechnology & Medical Research

More about the company